Research Lab Review

Thymosin beta-4: what the evidence shows, and what it does not

News ยท Thymosin beta-4

A new orthopaedic review finds no human evidence for thymosin beta-4 in tendon, muscle or bone repair, as two new animal and lab studies point in opposite directions.

A new review written for orthopaedic surgeons concludes that thymosin beta-4’s evidence for tendon, muscle and bone repair comes only from cell and rodent studies. Its human data come from eye, skin and heart research instead [1]. Two new preclinical papers point in different directions: in one, thymosin beta-4 sped wound closure in diabetic mice [2]. In the other, the same molecule helped brain tumor cells spread in laboratory and animal experiments [3]. Together they show why a lab finding about one tissue says little about another, or about people.

Key takeaways

  • A 2026 narrative review found that direct musculoskeletal evidence for thymosin beta-4 is limited to cell (in vitro) and rodent studies, with no controlled human orthopaedic trials [1].
  • The review notes that human experience with thymosin beta-4 comes from eye, skin and heart applications. It says these findings cannot establish musculoskeletal benefit or safety [1].
  • In diabetic mice, thymosin beta-4 (used as a comparison) and three related insect-derived thymosin proteins were linked to faster wound closure by day 8 [2].
  • A separate study found that thymosin beta-4 released by brain support cells promoted glioma growth and invasion in lab and animal models [3].

Compound light microscope on a bench in a biology laboratory

The orthopaedic review: plausible in the lab, unproven in patients

The review in the Journal of the American Academy of Orthopaedic Surgeons is a narrative review. It is not a systematic review or a meta-analysis [1]. The authors searched PubMed/MEDLINE, EMBASE and Scopus from inception through June 2026. They also read regulatory and antidoping sources [1]. The review covered thymosin beta-4, another investigational peptide called BPC-157, and a fragment of thymosin beta-4 [1].

For thymosin beta-4, the authors describe broader experimental and human experience than for the other peptides. That experience is in ophthalmic (eye), dermatologic (skin) and cardiovascular applications [1]. The direct evidence on tendons, muscle and bone, however, is limited to in vitro and rodent studies [1]. The authors state plainly that these nonorthopaedic findings “cannot establish musculoskeletal efficacy or safety” [1].

The review also points to a common mix-up. A seven-amino-acid fragment of thymosin beta-4 is often treated as if it were the full-length molecule. The authors say no one has shown that the two are biologically or clinically equivalent [1]. They also raise quality concerns about products sold commercially, including identity, purity, concentration, sterility and consistency from batch to batch [1].

The authors’ conclusion is direct. None of these agents has an FDA-approved musculoskeletal indication or controlled human orthopaedic efficacy evidence, and they say routine clinical use “cannot be currently recommended” [1]. They advise orthopaedic clinicians to ask patients about peptide use, to separate preclinical plausibility from clinical proof, and to counsel athletes about antidoping rules [1].

Limits: A narrative review summarizes the literature but does not pool data or formally grade bias. Its picture depends on which studies the authors chose to discuss [1].

Where the human data come from: the eye

The review identifies eye research as one of the main areas of human experience with thymosin beta-4 [1]. One example is a registered phase 3 trial, NCT02974907 (ARISE-2). It assessed the safety and efficacy of a thymosin beta-4 eye-drop solution in people with dry eye syndrome [4]. The registry lists the trial as completed, with the record last updated in October 2026 [4].

Limits: We had only the registry record, not the published results. This article therefore makes no claim about what the trial found [4]. Even a positive eye trial would say nothing about tendons or bone. A drop applied to the eye surface is a different tissue and setting from musculoskeletal repair [1].

Diabetic mouse wounds: thymosin beta-4 as the comparison

The study in Genes focused mainly on three recombinant thymosin proteins from the American cockroach, Periplaneta americana (called THY1, THY2 and THY3) [2]. Preparations from this insect have been used for wounds and ulcers in China, but their active ingredients are not well characterized [2]. Thymosin beta-4 served as the positive control and a salt solution (PBS) as the negative control [2].

This was an animal study in male ob/ob mice, a genetic model of obesity and diabetes [2]. The researchers applied each protein to the surface of full-thickness skin wounds. They tracked wound area and examined tissue with stains for skin structure, collagen and blood vessels (CD31) [2]. They also sequenced RNA from wound tissue on days 3 and 8 to see which genes changed [2].

On day 8, average wound closure was 95% to 97% in the THY1, THY2, THY3 and thymosin beta-4 groups. In the PBS group it was 81% [2]. Wounds that received any of the active proteins had more complete skin coverage and a larger CD31-positive area, a marker of blood vessels [2]. Collagen staining was higher than in controls only in the THY2 and THY3 groups [2]. On the gene level, THY3 overlapped most with thymosin beta-4. The analysis also found early metabolic changes, interferon-related signals and late keratinization (outer-skin formation) signals in the THY1, THY3 and thymosin beta-4 groups [2].

Limits: The abstract does not give the number of mice. Only male mice were studied, and the main result is a single time point (day 8) [2]. Gene-expression patterns show associations, not mechanisms. The authors themselves conclude only that the results support further preclinical study [2]. Mouse skin closes partly by contraction, unlike human skin, so these results do not show what would happen in people.

Brain tumors: the same molecule helping cancer spread

The Oncogene paper looked at glioblastoma, an aggressive brain cancer that spreads through the brain’s white matter [3]. The researchers combined studies of human tumor tissue, lab experiments and animal (in vivo) models [3]. The abstract does not report sample sizes.

The team found that oligodendrocyte-lineage cells build up at tumor borders. Oligodendrocytes are the cells that insulate nerve fibers in white matter. Factors these cells release increased glioma cell growth and movement [3]. Protein and RNA analyses pointed to thymosin beta-4 (gene name TMSB4X) from oligodendrocytes as a key factor. It activated a growth signal called AKT in tumor cells [3]. The tumors in turn released TGF-beta, which pushed oligodendrocytes to make more thymosin beta-4. This creates a self-reinforcing loop [3]. Blocking the interaction between tumor and oligodendrocytes, genetically or with drugs, reduced glioma spread along white matter in animal models [3].

Limits: This is preclinical work, and the abstract does not give the species or animal numbers [3]. It shows that thymosin beta-4 made by the body’s own cells can support tumor invasion in these models. It did not test thymosin beta-4 given from outside the body, and it does not show a cancer risk in people. Still, it is a reminder that a molecule that encourages cell movement and new blood vessels in a wound may do something similar in a tumor.

Reading these studies together

The three papers fit a pattern the orthopaedic review describes. A plausible mechanism and promising animal data do not equal clinical proof [1]. Thymosin beta-4’s effects on cell movement and blood vessel growth appear in wound models [2]. Related signaling also appears to support glioma spread [3]. Whether any effect is helpful or harmful seems to depend on the tissue and setting. That is one reason results in eye, skin or heart research cannot simply be applied to tendons or bone [1].

What we still don’t know

  • Whether thymosin beta-4 affects tendon, muscle or bone repair in people. No controlled human orthopaedic trials were identified [1].
  • What the completed phase 3 dry-eye trial found. Its registry record lists no results [4].
  • How the insect-derived thymosin proteins compare in female animals, at later time points, or in models closer to human skin [2].
  • Whether the glioma findings in lab and animal models apply to human patients, and whether thymosin beta-4 from outside the body has any bearing on tumor behavior [3].
  • Whether the seven-amino-acid fragment acts like the full-length molecule, and what commercial products actually contain [1].
  • Long-term safety in humans for musculoskeletal uses, which the review says has not been established [1].

References

  1. Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and [thymosin beta-4 fragment]. Journal of the American Academy of Orthopaedic Surgeons (2026). doi:10.5435/JAAOS-D-26-00049
  2. Comparative Transcriptomic Profiling of Diabetic Wound Responses to Recombinant Periplaneta americana Thymosin Isoforms in Male ob/ob Mice. Genes (2026). doi:10.3390/genes17101296
  3. Paracrine TMSB4X signaling from oligodendrocytes promotes diffuse glioma dissemination. Oncogene (2026). doi:10.1038/s41388-026-04029-8
  4. Assessment of the Safety and Efficacy of [thymosin beta-4 eye drops] Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2. ClinicalTrials.gov NCT02974907, status: completed.

Image credits

Free to use (CC0 / public domain); credited as a courtesy.

  • Interfilament Distance.jpg, by BuffetHawk (CC0, via wikimedia-commons): source
  • Compound Microscope.JPG, by Acagastya (CC0, via wikimedia-commons): source